查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1570679

5α 还原酶缺乏症市场：按类型、最终用户、年龄组、诊断方法、治疗 - 全球预测 2025-2030

5-Alpha Reductase Deficiency Market by Type (Primary 5-Alpha Reductase Deficiency, Secondary 5-Alpha Reductase Deficiency), End Users (Clinics, Hospitals, Research Institutes), Age Group, Diagnosis Technique, Treatment - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年5α-还原酶缺乏症市值为11.7亿美元，预计到2024年将达到12.8亿美元，复合年增长率为9.82%，到2030年将达到22.6亿美元。

5-α 还原酶缺乏症是一种罕见的遗传性疾病，其特征是将睪固酮转化为二氢睪固酮 (DHT) 的酵素存在缺陷，而二氢睪固酮对男性性发育非常重要。市场范围包括解决这些缺陷的药物、诊断和治疗性介入。它的需求源于它在使模糊的生殖器正常化、澄清性别认同以及管理相关心理后果方面的重要作用。应用领域包括产前诊断、新疗法的开发和潜在的基因疗法。主要的最终用途领域包括医院、罕见疾病专科诊所和专门从事遗传疾病的研究机构。

主要市场统计
基准年[2023] 11.7亿美元
预测年份 [2024] 12.8亿美元
预测年份 [2030] 22.6亿美元
复合年增长率（%） 9.82%

市场成长的推动因素包括对罕见遗传疾病的认识不断提高、CRISPR 等基因组编辑技术的进步以及医疗保健支出的增加。最新的机会在于个人化医疗，特别是针对个人基因特征的干预措施。公司可以透过投资与医疗保健提供者的伙伴关係来加强其市场地位，以促进早期诊断和治疗计划。此外，整合遗传咨询服务可以增强对消费者的价值提案。局限性包括该疾病的罕见性，从而限制了临床试验和市场投资。围绕基因编辑的伦理担忧可能会阻碍某些进步，包括开发新治疗方法的高成本和监管核准程序的复杂性。

该领域的创新可以集中在开发非侵入性诊断测试以及利用人工智慧进行预测分析和患者管理解决方案。整合荷尔蒙疗法和基因疗法的联合治疗的潜力可以为治疗功效和业务成长开闢重要途径。持续关注强有力的研究和发展至关重要，促进与学术机构和生物技术部门的合作也很重要。整体而言，该市场尚不发达，但前景广阔，相关人员需要平衡对创新研究和积极市场推广的重视，以有效利用成长机会。

市场动态：揭示快速发展的 5α 还原酶缺乏症市场的关键市场洞察

5α-还原酶缺乏症市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业减轻政治、地理、技术、社会和经济领域的风险，以及消费行为及其对製造成本的影响及其对采购趋势的影响。

波特五力：驾驭 5α 还原酶缺乏症市场的策略工具

波特的五力框架是了解 5α 还原酶缺乏症市场竞争格局的关键工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对 5α 还原酶缺乏症市场的影响

外部宏观环境因素在塑造 5α-还原酶缺乏症市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助企业预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解5α还原酶缺乏症市场的竞争状况

对 5α-还原酶缺乏症市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵 5α 还原酶缺乏症市场供应商的绩效评估

FPNV定位矩阵是评估5α还原酶缺乏症市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了 5α-还原酶缺乏症市场的成功之路

对于想要加强在全球市场的影响力的公司来说，对 5α-还原酶缺乏症市场进行策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争格局中的挑战，利用新的商机并取得长期成功。

该报告提供了涵盖主要焦点细分市场的全面市场分析。

1. 市场渗透率：对当前市场环境的详细回顾。

2. 市场开拓：辨识新兴市场的成长机会，评估现有产业的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检视市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 5α-还原酶缺乏症盛行率的增加增加了对先进诊断和治疗性介入的需求
      • 提高对遗传疾病的认识和了解，促进早期诊断和治疗
      • 医疗费用上涨和政府努力促进罕见遗传疾病的研发
      • 创新治疗方案和生物技术进步推动 5α-还原酶缺乏症治疗的成长
    • 抑制因素
      • 病患意识低落和诊断挑战阻碍了 5α 还原酶缺乏症市场的成长
    • 机会
      • 利用数位健康技术为 5α-还原酶缺乏症患者建立强大的患者支持网络。
      • 与国际製药公司合作，快速推动解决5-α还原酶缺乏症新治疗方法的临床试验
      • 与医疗保健提供者建立伙伴关係并创建综合护理模式以改善患者的生活品质
    • 任务
      • 严格的监管要求和核准流程减缓了新治疗方法的采用。 5α还原酶缺乏症市场
  • 市场区隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第 6 章 5α 还原酶缺乏症市场：依类型

  • 介绍
  • 原发性5α-还原酶缺乏症
    • 类型1
    • 2型
  • 次发性5α-还原酶缺乏症
    • 获得的
    • 先天性的

第 7 章 5α 还原酶缺乏症市场：依最终用户

  • 介绍
  • 诊所
  • 医院
  • 研究所
  • 专门治疗中心

第 8 章 5α 还原酶缺乏症市场：依年龄组

  • 介绍
  • 年轻又年轻
  • 成人
  • 儿科的

第 9 章 5α 还原酶缺乏症市场：透过诊断方法

  • 介绍
  • 基因检测
    • 染色体分析
    • DNA分析
  • 荷尔蒙测试
    • 双氢睪酮 (DHT) 水平
    • 血清睪固酮水平
  • 放射影像诊断
    • MRI
    • 超音波

第 10 章 5α 还原酶缺乏症市场：依治疗分类

  • 介绍
  • 荷尔蒙补充疗法
    • 雄激素
    • 雌激素
  • 监测和跟进
  • 心理支持
  • 手术介入
    • 生殖器重组
    • 性腺切除术

第11章北美和南美5α还原酶缺乏症市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区5α还原酶缺乏症市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第13章欧洲、中东和非洲5α还原酶缺乏症市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-2B5802CFE14D

The 5-Alpha Reductase Deficiency Market was valued at USD 1.17 billion in 2023, expected to reach USD 1.28 billion in 2024, and is projected to grow at a CAGR of 9.82%, to USD 2.26 billion by 2030.

5-Alpha Reductase Deficiency is a rare genetic condition characterized by a defect in the enzyme responsible for converting testosterone into dihydrotestosterone (DHT), crucial for male sexual development. The market scope involves pharmaceuticals, diagnostics, and therapeutic interventions addressing these deficiencies. The necessity stems from its critical role in normalizing ambiguous genitalia, providing gender identity clarity, and managing associated psychological impacts. Application areas include prenatal diagnostics, novel therapeutic agent development, and potentially gene therapy. Key end-use segments are hospitals, specialized clinics for rare diseases, and research institutions focused on genetic disorders.

KEY MARKET STATISTICS
Base Year [2023] USD 1.17 billion
Estimated Year [2024] USD 1.28 billion
Forecast Year [2030] USD 2.26 billion
CAGR (%) 9.82%

Market growth is propelled by rising awareness about rare genetic conditions, advances in genome editing technologies like CRISPR, and increasing healthcare expenditure. Latest opportunities lie in personalized medicine, particularly in tailoring interventions that suit individual genetic profiles. Companies can bolster their market position by investing in partnerships with healthcare providers to facilitate early diagnosis and therapeutic planning. Additionally, integrating genetic counseling services enhances the value proposition for consumers. Limitations include the rarity of the condition, resulting in limited clinical trials and market investments. Ethical concerns surrounding gene editing could impede certain advancements, while challenging factors include high development costs for novel therapies and procedural complexities in regulatory approvals.

Innovation within this field can pivot towards developing non-invasive diagnostic tests and leveraging artificial intelligence for predictive analytics and patient management solutions. The potential of combination therapies, integrating hormonal treatments with gene therapy, may open significant avenues for treatment efficacy and business growth. Continued focus on robust R&D, alongside fostering collaborations with academic and biotech sectors, is essential. Overall, the market displays a nascent yet promising nature, suggesting that stakeholders need a balanced emphasis on innovative research and active market promotion to capitalize on growth opportunities effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving 5-Alpha Reductase Deficiency Market

The 5-Alpha Reductase Deficiency Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of 5-alpha reductase deficiency raising demand for advanced diagnostic and therapeutic interventions
    • Increasing awareness and better understanding of genetic disorders enhancing early diagnosis and treatment
    • Rising healthcare expenditure and government initiatives promoting research and development in rare genetic conditions
    • Innovative treatment options and biotechnological advancements driving growth in 5-alpha reductase deficiency treatments
  • Market Restraints
    • Limited patient awareness and diagnosis challenges hinder market growth for 5-alpha reductase deficiency
  • Market Opportunities
    • Leveraging digital health technologies to create a robust patient support network for those with 5-alpha reductase deficiency
    • Collaborating with international pharmaceutical companies to fast-track clinical trials for new treatments addressing 5-alpha reductase deficiency
    • Establishing partnerships with healthcare providers for integrated care models to enhance quality of life for 5-alpha reductase deficiency patients
  • Market Challenges
    • Stringent regulatory requirements and approval processes, slowing down the introduction of new treatments in the 5-alpha reductase deficiency market

Porter's Five Forces: A Strategic Tool for Navigating the 5-Alpha Reductase Deficiency Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the 5-Alpha Reductase Deficiency Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the 5-Alpha Reductase Deficiency Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the 5-Alpha Reductase Deficiency Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the 5-Alpha Reductase Deficiency Market

A detailed market share analysis in the 5-Alpha Reductase Deficiency Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the 5-Alpha Reductase Deficiency Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the 5-Alpha Reductase Deficiency Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the 5-Alpha Reductase Deficiency Market

A strategic analysis of the 5-Alpha Reductase Deficiency Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the 5-Alpha Reductase Deficiency Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan plc, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis International AG, Novo Nordisk A/S, Pfizer Inc., Roche Holding AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the 5-Alpha Reductase Deficiency Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Primary 5-Alpha Reductase Deficiency and Secondary 5-Alpha Reductase Deficiency. The Primary 5-Alpha Reductase Deficiency is further studied across Type 1 and Type 2. The Secondary 5-Alpha Reductase Deficiency is further studied across Acquired and Congenital.
  • Based on End Users, market is studied across Clinics, Hospitals, Research Institutes, and Specialty Treatment Centers.
  • Based on Age Group, market is studied across Adolescents, Adults, and Pediatric.
  • Based on Diagnosis Technique, market is studied across Genetic Testing, Hormone Testing, and Radiological Imaging. The Genetic Testing is further studied across Chromosomal Analysis and DNA Analysis. The Hormone Testing is further studied across Dihydrotestosterone (DHT) Levels and Serum Testosterone Levels. The Radiological Imaging is further studied across MRI and Ultrasound.
  • Based on Treatment, market is studied across Hormone Replacement Therapy, Monitoring And Follow-Up, Psychological Support, and Surgical Interventions. The Hormone Replacement Therapy is further studied across Androgens and Estrogens. The Surgical Interventions is further studied across Genital Reconstruction and Gonadectomy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of 5-alpha reductase deficiency raising demand for advanced diagnostic and therapeutic interventions
      • 5.1.1.2. Increasing awareness and better understanding of genetic disorders enhancing early diagnosis and treatment
      • 5.1.1.3. Rising healthcare expenditure and government initiatives promoting research and development in rare genetic conditions
      • 5.1.1.4. Innovative treatment options and biotechnological advancements driving growth in 5-alpha reductase deficiency treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Limited patient awareness and diagnosis challenges hinder market growth for 5-alpha reductase deficiency
    • 5.1.3. Opportunities
      • 5.1.3.1. Leveraging digital health technologies to create a robust patient support network for those with 5-alpha reductase deficiency
      • 5.1.3.2. Collaborating with international pharmaceutical companies to fast-track clinical trials for new treatments addressing 5-alpha reductase deficiency
      • 5.1.3.3. Establishing partnerships with healthcare providers for integrated care models to enhance quality of life for 5-alpha reductase deficiency patients
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements and approval processes, slowing down the introduction of new treatments in the 5-alpha reductase deficiency market
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. 5-Alpha Reductase Deficiency Market, by Type

  • 6.1. Introduction
  • 6.2. Primary 5-Alpha Reductase Deficiency
    • 6.2.1. Type 1
    • 6.2.2. Type 2
  • 6.3. Secondary 5-Alpha Reductase Deficiency
    • 6.3.1. Acquired
    • 6.3.2. Congenital

7. 5-Alpha Reductase Deficiency Market, by End Users

  • 7.1. Introduction
  • 7.2. Clinics
  • 7.3. Hospitals
  • 7.4. Research Institutes
  • 7.5. Specialty Treatment Centers

8. 5-Alpha Reductase Deficiency Market, by Age Group

  • 8.1. Introduction
  • 8.2. Adolescents
  • 8.3. Adults
  • 8.4. Pediatric

9. 5-Alpha Reductase Deficiency Market, by Diagnosis Technique

  • 9.1. Introduction
  • 9.2. Genetic Testing
    • 9.2.1. Chromosomal Analysis
    • 9.2.2. DNA Analysis
  • 9.3. Hormone Testing
    • 9.3.1. Dihydrotestosterone (DHT) Levels
    • 9.3.2. Serum Testosterone Levels
  • 9.4. Radiological Imaging
    • 9.4.1. MRI
    • 9.4.2. Ultrasound

10. 5-Alpha Reductase Deficiency Market, by Treatment

  • 10.1. Introduction
  • 10.2. Hormone Replacement Therapy
    • 10.2.1. Androgens
    • 10.2.2. Estrogens
  • 10.3. Monitoring And Follow-Up
  • 10.4. Psychological Support
  • 10.5. Surgical Interventions
    • 10.5.1. Genital Reconstruction
    • 10.5.2. Gonadectomy

11. Americas 5-Alpha Reductase Deficiency Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific 5-Alpha Reductase Deficiency Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa 5-Alpha Reductase Deficiency Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Allergan plc
  • 3. Amgen Inc.
  • 4. Astellas Pharma Inc.
  • 5. AstraZeneca PLC
  • 6. Bayer AG
  • 7. Biogen Inc.
  • 8. Bristol-Myers Squibb Company
  • 9. Eli Lilly and Company
  • 10. Gilead Sciences, Inc.
  • 11. GlaxoSmithKline plc
  • 12. Johnson & Johnson
  • 13. Merck & Co., Inc.
  • 14. Novartis International AG
  • 15. Novo Nordisk A/S
  • 16. Pfizer Inc.
  • 17. Roche Holding AG
  • 18. Sanofi S.A.
  • 19. Takeda Pharmaceutical Company Limited
  • 20. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. 5-ALPHA REDUCTASE DEFICIENCY MARKET RESEARCH PROCESS
  • FIGURE 2. 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. 5-ALPHA REDUCTASE DEFICIENCY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. 5-ALPHA REDUCTASE DEFICIENCY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. 5-ALPHA REDUCTASE DEFICIENCY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. 5-ALPHA REDUCTASE DEFICIENCY MARKET DYNAMICS
  • TABLE 7. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE 1, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE 2, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ACQUIRED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CONGENITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SPECIALTY TREATMENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CHROMOSOMAL ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DNA ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIHYDROTESTOSTERONE (DHT) LEVELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SERUM TESTOSTERONE LEVELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ANDROGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ESTROGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY MONITORING AND FOLLOW-UP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PSYCHOLOGICAL SUPPORT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENITAL RECONSTRUCTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GONADECTOMY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 136. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 138. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 140. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 142. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 144. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 146. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 148. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 150. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 151. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 152. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 153. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 154. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 155. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 156. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 157. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 158. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 159. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 160. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 162. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 163. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 164. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 165. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 166. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 167. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 168. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 169. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 170. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 171. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 172. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 174. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 175. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 176. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 177. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 178. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 179. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 180. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 181. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 182. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 183. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 184. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 186. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 187. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 188. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 189. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 190. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 191. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 192. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 193. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 194. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 195. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 196. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 198. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 199. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 200. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 201. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 202. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 203. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 204. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 205. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 206. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 207. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 208. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 210. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 211. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 212. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 213. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 214. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 215. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 216. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 217. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 218. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 219. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 220. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 222. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 223. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 224. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 225. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 226. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 227. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 228. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 229. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 230. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 231. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 232. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 234. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 235. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 236. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 244. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 246. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 247. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 248. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 249. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 250. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 251. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 252. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 253. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 254. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 255. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 256. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 258. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 259. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 260. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 261. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 262. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 263. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 264. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 265. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 266. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 267. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 268. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 270. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 271. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 272. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 273. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 274. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 275. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 276. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 277. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 278. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 279. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 293. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 294. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 295. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 296. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 297. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 298. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)

TABLE 29